Trial Profile
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Busulfan; Cyclophosphamide; Fludarabine; Melphalan; Methotrexate; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
- Indications Graft-versus-host disease; Myelofibrosis
- Focus Therapeutic Use
- 17 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2021 Planned End Date changed from 11 Jun 2026 to 28 Dec 2025.
- 13 Dec 2021 Planned primary completion date changed from 11 Dec 2023 to 28 Dec 2022.